Biotech

Curanex Pharmaceuticals Inc. (NASDAQ:CURX) on Wednesday highlighted five additional patient cases that management believes further support the potential of its lead candidate, Phyto-N, in cancer cachexia. Patient Cases Suggest Functional Recovery Trends The company highlighted five additional...

Insmed Incorporated (NASDAQ:INSM) on Tuesday shared the Phase 2b CEDAR study results for brensocatib. The study did not meet its primary or secondary efficacy endpoints, leading Insmed to discontinue its hidradenitis suppurativa program. Insmed Discontinues Failed Program The Phase 2b CEDAR study,...

In March, Merck & Co Inc. (NYSE:MRK) agreed to acquire Terns Pharmaceuticals Inc. (NASDAQ:TERN), as the U.S. drugmaker accelerates efforts to offset looming revenue risks tied to its blockbuster cancer immunotherapy Keytruda. The deal consideration is $53.00 per share in cash for an approximate...

Outlook Therapeutics (NASDAQ:OTLK) announced on Monday that it has submitted a formal dispute resolution request (FDRR) to the U.S. Food and Drug Administration (FDA) regarding its ONS-5010/LYTENAVA. The update comes after receiving a Complete Response Letter (CRL) in December 2025 for its...

Gilead Sciences Inc. (NASDAQ:GILD) shares are down on Tuesday as the company announced a $3.15 billion acquisition of Tubulis GmbH. The Foster City, California-based firm aims to enhance its oncology pipeline. The acquisition adds TUB-040, a promising antibody-drug conjugate (ADC) for the treatment...

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) shares are down on Tuesday as the company announced broad alignment with the FDA regarding the registration path for its CRB-701 treatment. • Corbus Pharmaceuticals stock is showing weakness. What’s driving CRBP stock lower? FDA...

Biogen Inc. (NASDAQ:BIIB) on Tuesday entered into an agreement with Alloy Therapeutics Inc. to accelerate the development of antisense therapies targeting multiple undisclosed indications. Waltham, Massachusetts-based Alloy will receive an upfront payment and stands to earn additional milestone-...

Organogenesis Holdings Inc. (NASDAQ:ORGO) shares are up during Tuesday’s premarket session following the company’s announcement of achieving the primary endpoint in a randomized controlled trial evaluating PuraPly AM for managing non-healing diabetic foot ulcers. Organogenesis Trial...

Sanofi SA (NASDAQ:SNY) on Tuesday reported Phase 2 data for its experimental therapy lunsekimig in chronic respiratory diseases, highlighting meaningful improvements in asthma and nasal polyp patients, while showing mixed outcomes in a separate skin disorder study. Strong Outcomes In Asthma Study...

Viridian Therapeutics Inc. (NASDAQ:VRDN) shares fell sharply Monday following topline Phase 3 data from Amgen Inc. (NASDAQ:AMGN) for TEPEZZA in thyroid eye disease (TED), intensifying competitive pressure in the space. Amgen Data Raises Competitive Pressure The Phase 3 TEPEZZA OBI trial met its...

Denali Therapeutics (NASDAQ:DNLI) shares are down on Monday as the company announced it has regained full rights to its investigational therapy DNL593 from Takeda Pharmaceutical Co. Ltd. (NYSE:TAK) Takeda Ends Drug Partnership For Strategic Reasons Takeda on Friday notified Denali Therapeutics...

ImmunityBio Inc (NASDAQ:IBRX) shares were up during Monday’s premarket session, but dipped as the company addresses compliance issues raised by the U.S. Food and Drug Administration (FDA). The FDA issued a warning to ImmunityBio, alleging that the company made unsupported claims that Anktiva...

Amgen Inc. (NASDAQ:AMGN) shares are down on Monday after the company announced topline results from a Phase 3 trial of TEPEZZA, which is administered via an on-body injector for patients with moderate-to-severe active Thyroid Eye Disease. Trial Meets Primary Endpoint The Phase 3 TEPEZZA OBI trial...

Lipocine Inc. (NASDAQ:LPCN) shares are up during Monday’s premarket session after the company’s stock plunged almost 78% on Thursday following disappointing trial data. On Thursday, the company said LPCN 1154 did not meet its primary endpoint in a Phase 3 trial for postpartum depression...

Curanex Pharmaceuticals Inc. (NASDAQ:CURX) on Monday said that a recent patient case study may reinforce its strategic push into cancer cachexia, a severe wasting condition tied to advanced cancers with limited treatment options. Last week, Curanex added a new core indication, cancer cachexia, to...